FDA expedites review of Biogen's multiple sclerosis drug

07/8/2009 | American City Business Journals

The FDA granted fast-track designation to Biogen Idec's PEGylated interferon beta-1a, a multiple sclerosis medicine. The drug's potential to treat patients with only one or two injections a month might have been a factor in the agency's decision. Biogen plans on "working closely with the FDA to expedite the compound's development and review process," a company official said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI